Leap Therapeutics’ (LPTX) Neutral Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Leap Therapeutics (NASDAQ:LPTX) in a report published on Thursday morning,Benzinga reports.

Several other equities research analysts have also recently weighed in on LPTX. Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 29th. Robert W. Baird downgraded shares of Leap Therapeutics from an “outperform” rating to a “neutral” rating and decreased their target price for the company from $9.00 to $1.25 in a research report on Wednesday, January 29th.

Leap Therapeutics Price Performance

Shares of NASDAQ LPTX opened at $0.32 on Thursday. Leap Therapeutics has a 1 year low of $0.31 and a 1 year high of $4.79. The firm has a market cap of $12.13 million, a PE ratio of -0.16 and a beta of 0.35. The company has a 50 day simple moving average of $0.69 and a 200 day simple moving average of $2.16.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. As a group, research analysts anticipate that Leap Therapeutics will post -1.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in LPTX. Prosperity Wealth Management Inc. bought a new stake in shares of Leap Therapeutics during the 4th quarter valued at about $63,000. HighTower Advisors LLC bought a new position in shares of Leap Therapeutics during the 3rd quarter worth approximately $65,000. Jane Street Group LLC acquired a new stake in shares of Leap Therapeutics during the 4th quarter worth approximately $107,000. Dauntless Investment Group LLC acquired a new position in shares of Leap Therapeutics during the 4th quarter valued at $144,000. Finally, NewEdge Advisors LLC boosted its stake in Leap Therapeutics by 1,668,066.7% during the fourth quarter. NewEdge Advisors LLC now owns 50,045 shares of the company’s stock worth $144,000 after acquiring an additional 50,042 shares in the last quarter. 30.46% of the stock is owned by institutional investors.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.